We analyzed the kinetic and spatial patterns characterizing activation of the MAP kinases ERK 1 and 2 (ERK1/2) by the three α 1 -adrenoceptor (α 1 -AR) subtypes in HEK293 cells and the contribution of two different pathways to ERK1/2 phosphorylation: protein kinase C (PKC)-dependent ERK1/2 activation and internalization-dependent ERK1/2 activation. The different pathways of phenylephrine induced ERK phosphorylation were determined by western blot, using the PKC inhibitor Ro 31-8425, the receptor internalization inhibitor concanavalin A and the siRNA targeting β-arrestin 2. Receptor internalization properties were studied using CypHer5 technology and VSV-G epitope-tagged receptors. Activation of α 1A -and α 1B -ARs by phenylephrine elicited rapid ERK1/2 phosphorylation that was directed to the nucleus and inhibited by Ro 31-8425. Concomitant with phenylephrine induced receptor internalization α 1A -AR, but not α 1B -AR, produced a maintained and PKC-independent ERK phosphorylation, which was restricted to the cytosol and inhibited by β-arrestin 2 knockdown or concanavalin A treatment. α 1D -AR displayed constitutive ERK phosphorylation, which was reduced by incubation with prazosin or the selective α 1D antagonist BMY7378. Following activation by phenylephrine, α 1D -AR elicited rapid, transient ERK1/2 phosphorylation that was restricted to the cytosol and not inhibited by Ro 31-8425. Internalization of the α 1D -AR subtype was not observed via CypHer5 technology. The three α 1 -AR subtypes present different spatio-temporal patterns of receptor internalization, and only α 1A -AR stimulation translates to a late, sustained ERK1/2 phosphorylation that is restricted to the cytosol and dependent on β-arrestin 2 mediated internalization.
Introduction
The α 1 -adrenoceptors (α 1 -ARs) have been extensively investigated with regard to their pharmacology and structure-function relationship. In contrast, less is known about their regulatory properties, and the trafficking and protein interactions involved in these processes. They are heptahelical transmembrane proteins that belong to the G proteincoupled receptor (GPCR) superfamily. Upon agonist binding, α 1 -ARs stimulate activation and dissociation of the α and βγ subunits of G q / 11 proteins [1] , and promote PKC activation [2] , as well as an increase of intracellular IP3 and calcium content [3, 4] . Extracellular signalregulated kinase (ERK)/mitogen-activated protein kinase (MAPK) activation promoted by the different α 1 -AR subtypes has also been detected [5, 6] . Termination of GPCR signaling is triggered by the phosphorylation of the agonist-occupied receptor by G-protein-coupled receptor-kinases (GRKs) and the second-messenger-dependent protein kinases PKA and PKC [5, 7] , promoting high affinity binding of cytoplasmatic β-arrestins to the receptor, resulting in its desensitization and endocytosis [8] .
Three different α 1 -AR subtypes (α 1A , α 1B and α 1D ) have been cloned and exhibit differences in amino acid sequence and antagonist binding affinities [9, 10] . Different cellular localization is also exhibited by the three subtypes: α 1B -AR is primarily expressed on the cell surface [11] , α 1A -AR is detected not only on the cell surface, but also intracellularly [12] . In contrast, α 1D -AR appears to be localized perinuclearly and produces ERK1/2 activation in the absence of agonists [11] . This α 1D -AR constitutive activity has also been measured by a spontaneous increase in the resting tone [13] [14] [15] [16] and calcium and IP3 accumulation [17, 18] in rat aorta, where the main α 1 -AR subtype is α 1D .
An increasing number of studies indicate that the α 1 -AR subtypes display striking differences in their internalization properties and, although controversial, it has been suggested that while α 1B -AR undergoes robust agonist-induced endocytosis, α 1A -AR does not [19] . Other reports disagree and suggest that α 1A -AR also internalizes upon agonist activation, although to a lesser extent than the α 1B -AR, and that α 1D -AR is constitutively internalized [12, 20] . It has also been suggested that α 1A -AR is located in lipid rafts under basal conditions, but exits from these rafts following stimulation, therefore allowing endocytosis [21] .
Recently, distinct models of regulation of ERK1/2 activation over time after GPCR activation have been proposed and for many GPCRs, it has been shown that β-arrestin recruitment and receptorendocytosis are implicated in ERK1/2 activation [22] . For example, angiotensin II activation of the AT 1A receptor elicits both, a rapid (peak 2 min), G protein-dependent, ERK1/2 activation and a delayed (peak 5-10 min) and persistent ERK1/2 activation, that is β-arrestin2-dependent [23] . Similar patterns were found for the β 2 -AR [24] and the parathyroid hormone receptor [25] .
To our knowledge, no coherent analysis of the temporal profile of internalization and ERK1/2 MAPK activation by the three α 1 -AR subtypes is available. In the present work, we performed a study of the temporal and spatial patterns of ERK1/2 activation after stimulation of each human α 1 -AR stably expressed in HEK293 cells. We explored whether such signals were modified by β-arrestin 2 transcriptional silencing, by blocking receptor endocytosis with concanavalin A (ConA), and by inhibiting PKC with a selective inhibitor. We also studied the different properties of receptor internalization into acidic endosomes by using CypHer5 technology [26, 27] and VSV-G epitope tagged receptors to shed light into potential differences between the α 1 -AR subtypes.
Materials and methods

Antibodies and reagents
The antibodies used included phospho-p42/44 ERK MAPK (Thr202/ Thr204) and p42/44 ERK MAPK (Cell Signaling Technology, Beverly, MA). CypHer5-anti-VSV-G tag antibody (PA45407), horseradish peroxidase-labeled secondary antibodies and chemiluminescent reagents were from GE Healthcare (Amersham, Buckinghamshire, UK). 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) was purchased from Panreac (Barcelona, Spain). Anti-actin antibody (A2066), concanavalin A (ConA), phenylephrine, Ro 31-8425, prazosin, antibiotic G418, 5-methylurapidil, BMY7378, phentolamine, ethylenediaminetetraacetic acid (EDTA), Nonidet™ P-40, phenylmethanesulfonyl fluoride (PMSF), sodium vanadate, sodium fluoride, ditiothreitol and poly-L-lysine (molecular weight 70,000-150,000) were purchased from Sigma (Sigma, St Louis, MO).
Construction of the VSV-G-Tagged α 1 -AR subtypes
The VSV-G (YTDIEMNRLGK) epitope tag was introduced immediately upstream of each human α 1A -AR, α 1B -AR and α 1D -AR. The aminoterminal primer (5′-AAAAAAAAGGATCCGCCACCATGTACACCGATATAG AGATGAACAGGCTGGGAAAGGTGTTTCTCTCGGGAAATGC-3′) or (5′-AAA AAAAGCTTCCACCATGTACACTGATATCGAAATGAACCGCCTGGGTAAGAA TCCCGACCTGGACACCG-3′) or (5′-AAAAAAAGCTTCCACCATGTACACTG ATATCGAAATGAACCGCCTGGGTAAGACTTTCCGCGATCTCCTGAGCG-3′) was used to incorporate a VSV-G tag, a consensus Kozak sequence and BamHI, HindIII and HindIII sites for α 1A -, α 1B -and α 1D -AR, respectively. Depending on the subtype used as a template, the following carboxyl terminal reverse primer was hybridized: α 1A -AR, 5′-AAAAAAAACTCG AGCTAGACTTCCTCCCCGTTC-3′; α 1B -AR, 5′AAAAAGAATTCCTAAAACTG CCCGGGCGC-3′; and α 1D -AR, 5′-AAAAAGAATTCTTAAATATCGGTCTCCC GTAGGTTGC-3′ respectively, incorporating a XhoI site, EcoRI and EcoRI sites downstream of the coding sequence. All the PCR fragments were subsequently cloned into the plasmid pcDNA3 (Invitrogen, Paisley, Renfrewshire, UK) by in-frame ligation. Construct sequences were confirmed by nucleotide sequencing.
Cell culture and transfection
HEK293 cells were grown in Dulbecco's modified Eagle's minimum essential medium (Sigma) supplemented with 10% newborn calf serum (Gibco BRL, Gaithersburg, MD), L-glutamine 2 mM (Gibco BRL), 100 μg/ml streptomycin and 100 units/ml penicillin at 37°C in a humidified atmosphere of 5% CO 2 . Cells were transfected by electroporation (300 V, 50 μs, 2 mm gap) using a Multiporator (Eppendorf AG, Hamburg, Germany). After 48 h, cells were selected with G418 400 μg/ml to identify stably expressing clones. All the experiments were performed at around 75% cell confluence.
RNA extraction and quantitative reverse-transcription polymerase chain reaction
RNA extraction and quantitative reverse-transcription polymerase chain reaction was performed as previously described [28, 29] . The threshold cycle (Ct) values obtained for each gene were referenced to GAPDH and converted into the linear form using the term 2 −ΔCt as a value directly proportional to the copy number of mRNA. ]prazosin concentrations ranging from 0.01 to 6 nM. The experiments were terminated by rapid filtration through fiberglass filters (Schleicher and Schuell, GF 52) pre-soaked in 0.3% polyethyleneimine using a Brandel cell harvester (M24R). The filters were then washed three times with 4 ml of ice cold 50 mM Tris-HCl buffer (pH 7.5), and filter bound radioactivity was determined by liquid scintillation counting. Nonspecific binding was measured in the presence of 10 μM phentolamine. The binding data were analyzed by non-linear regression using Prism, version 4.0 (Graph Pad Software; San Diego, California, USA) to determine the dissociation constant (K d ), and the maximum number of binding sites (B max ) for the saturation data. The saturation data were fitted to hyperbolic functions (one or two sites). The best fit to the one-site or twosites was evaluated using the F-test (P b 0.05).
Saturation binding experiments
β-Arrestin 2 siRNA knockdown
The expression of β-arrestin 2 was silenced using HP validated siRNA duplexes targeting human ARRB2 (Hs_ARRB2_10 siRNA; Catalog no. SI02776928, Qiagen). AllStars non-targeting siRNA (Catalog no. 1027284, Qiagen) was used as negative control. The day before transfection, cells were seeded in 30 mm dishes in regular growth medium without antibiotics and grown overnight. The day of transfection, Lipofectamine™2000 (Invitrogen)-siRNA complexes were prepared in Opti-MEM I reduced serum medium according to manufacturer's protocol. Cells were transfected with either 50 nM β-arrestin 2 siRNAs or non-targeting control siRNA complexes for 6 h followed by replacement with fresh growth medium including antibiotics. Transfected cells were assayed 48 h post-transfection. Suppression of the target gene was confirmed by western blot.
2.7. Real-time imaging of the internalization of the α 1 -AR subtypes to acidified endosomes in HEK293 cells HEK293 cells stably expressing the N-terminal VSV-G tagged human α 1A -, α 1B -and α 1D -AR subtypes were plated onto poly-L-lysine coated sterile coverslips 48 h before experimentation. Live cells were washed three times with cold Krebs-Ringer-Hepes buffer (KRH, 120 mM NaCl, 25 mM HEPES, 4.8 mM KCl, 1.2 mM MgSO 4 and 1.3 mM CaCl 2 at pH 7.4) at 4°C and were then incubated with CypHer5E linked anti-VSV-G antibody (GE Healthcare, Amersham, Buckinghamshire, UK) at 5 μg/ml in KRH buffer at 4°C for 1 h. After washing with KRH buffer at 4°C, coverslips were rapidly mounted into a flow chamber bath (Attofluor, Molecular Probes; Eugene, OR), placed on the microscope stage in a 95% air and 5% CO 2 atmosphere at 37°C. At this time, cells were exposed to control pre-warmed KRH buffer or buffer supplemented either with ConA (250 μg/ml) or prazosin (10 μM) for 30 min. After incubation with the aforementioned solutions, the zero time was set up immediately before adding phenylephrine (100 μM) to the imaging chamber and the system was set to acquire images at 5-min intervals for 15 min. A set of control experiments without additions was performed. A laser-scanning confocal inverted microscope (LEICA TCS SP2 (DM-IRBE), equipped with a 60× oil HCX PL APO (1.32 numerical aperture) objective, was used to acquire images. The excitation wavelength was 633 nm using a helium/neon laser and the emitted fluorescence was detected with a 650 nm long pass filter. Image processing and analysis were carried out using MetaMorph, version 6.1r3 (Universal Imaging Corporation) and the Leica software, v.2.61. Internalization kinetic was quantified at different times, by measuring the intensity of 5 defined line segments in the cytosolic region of the cell. We calculated the normalized signal for each line segments at each time point as Ii/I0, where I0 is the intensity taken before agonist stimulation for each segment. For each experiment, 5-8 cells were quantified. Data represent the mean of more than four independent experiments.
Preparation of cellular extracts and immunoblotting
HEK293 cells on 60 × 15mm plates were starved for 4 h in serum-free medium. Prior to stimulation with phenylephrine, cells were treated for 30 min with ConA (250 μg/ml) or with Ro 31-8425 (1 μM) for 15 min, where indicated. After stimulation, cells were washed once with cold PBS and lysed by rotating 30 min at 4°C with 500 μl of RIPA buffer (50 mM HEPES, 150 mM NaCl, 10% glycerol, 1.5 mM MgCl 2 , 0.1% SDS, 1 mM EGTA, 1% Triton-X 100 and 1% sodium deoxycholate) containing protease inhibitor cocktail (Complete®, Roche Applied Science) and phosphatase inhibitor cocktail (PhosSTOP®, Roche Applied Science). Sonication with a Microson™ XL 2000 Ultrasonic Liquid Processor and storage at −80°C followed. The protein content was measured by the Bradford method (Bio-Rad, Hercules CA). 15 μg of cellular extracts was incubated with SDS-sample buffer (2% SDS, 60 mM Tris buffer, 5% β-mercaptoethanol, 0.01% bromophenol blue and 10% glycerol) at 40°C for 30 min, separated on 10% SDSpolyacrylamide gels and transferred to PVDF membranes for immunoblotting. Prior to antibody incubation, membranes were blocked in phosphate-buffered saline with 0.1% Tween 20 (PBST) plus 3% BSA (albumin from bovine serum, Sigma, St Louis, MO). Phospho-p42/44 MAPK (Thr202/ Thr204) and p42/44 MAPK antibodies (Cell Signaling Technology), β-arrestin or the actin antibody (Sigma St Louis, MO) were incubated overnight at 4°C, 1/500 for the p42/44 MAPK and 1/2500 for actin diluted. Membranes were then washed three times with PBST, incubated with an anti-rabbit IgG horseradish peroxidase-conjugated secondary antibody (GE Healthcare, Amersham Buckinghamshire, UK) at 1/2500 for 45 min at room temperature, and was washed extensively with PBST before chemiluminescent detection was performed using the ECL Western Blotting Detection Reagents (GE Healthcare). Images were captured with an AutoChemi System (uvp Bioimaging Systems. Cambridge, UK), and band intensity was measured using LabWorks Image acquisition and Analysis (Ver. 4.6 uvp Bioimaging Systems, Cambridge, UK).
Confocal microscopy immunocytochemistry
HEK293 cells on poly-L-lysine coated 35 mm glass bottom dishes were starved for 4 h in serum free medium prior to stimulation. After stimulation, cells were fixed with 6% formaldehyde in PBS. Fixed cells were permeabilized with 0.01% Triton in PBS containing 2% BSA for 90 min, incubated with the phospho-p42/44 MAPK (Thr202/Thr204) antibody (Cell Signaling Technology, 1:200) at room temperature overnight, and repeatedly washed using PBS. Incubation of the secondary antibody Alexa Fluor 488 goat anti-rabbit (Molecular Probes; Eugene, OR, 1:1000) was performed for 20 min at room temperature followed by repeated washes using PBS. Then cells were incubated with Hoechst 33342 (Molecular Probes; Eugene, OR, 1:1000) for 15 min in darkness at room temperature on glass slides using Mowiol reagent 4-88 (Calbiochem, Darmstadt, Germany). Confocal images were obtained on a LEICA TCS SP2 (DM-IRB) laser scanning microscope using either the line 488 nm and emission 510-570 nm filter set for Alexa 488 or the 352 and 364 nm excitation and emission 390-480 nm filter set for Hoechst. A z-series of images was acquired at 2 μm steps to produce individual z-stacks. Interaction of Hoechst and p-ERK signals at the same z-stack was depicted in white by colocalization analysis with the Leica software, v2.61.
Statistical analysis
The results are presented as the mean ± S.E.M. for n experiments. A statistical analysis was performed by the two-way ANOVA or by the Student's t-test (GraphPad Software, Inc., San Diego, CA, USA). Significance was defined as P b 0.05.
Results
Using real-time RT-PCR, saturation radioligand binding techniques, immunocytochemistry and fluorescent ligands we confirmed that the three α 1 -ARs, and the corresponding VSV-G-tagged α 1 -ARs, were stably expressed in the HEK293 cell lines generated (Supplemental data 1 and 2). We found different expression levels of the three α 1 -AR subtypes, especially remarkable for the α 1D -subtype in binding but not in PCR assays. Considering the magnitude of the signals elicited by the agonist and in agreement with previous works [30] , we propose that this apparent lower Bmax observed, could be interpreted as a lower binding of the α 1D subtype to radioligands and not as a reduced protein expression.
3.1. Subtype-specific kinetic pattern of ERK1/2 activation ERK1/2 activation in the transfected HEK293 cells was promoted by α 1 -AR stimulation by phenylephrine (PE). The ERK1/2 phosphorylation induced by each α 1 -AR subtype following addition of PE was completely blocked in the presence of the α 1 -AR antagonist prazosin (PZ) (Supplemental data 2A). Furthermore, non-transfected cells showed no ERK1/2 phosphorylation after incubation with PE. The effect of different PE concentrations on ERK1/2 activation resulted in concentration-dependent responses (Supplemental data 2B) that varied for the three subtypes with α 1A displaying the lowest sensitivity (pED 50 α 1A -AR: 4.325 ± 0.14; pED 50 α 1B -AR: 6.838 ± 0.12; pED 50 α 1D -AR: 6.153 ± 0.16). This corresponds to previous results found when measuring IP 3 generation, contractile response or intracellular Ca 2+ increase [4, 9, 14, 28] . We selected 100 μM PE for subsequent experiments to ensure that ERK1/2 phosphorylation by all three α 1 -AR subtypes was observed. This high dose of PE has also been used in other studies where the ERK1/2 activation by α 1 -ARs was investigated [11, 12] . As we have previously reported different kinetic profiles of α 1A -and α 1D -AR responses when studying contractile properties of blood vessels [13, 16] , we performed a spatio-temporal analysis to examine if the same was true for α 1 -AR subtype activation of ERK1/2. As shown in Fig. 1 or Supplemental data 3 and as previously described, the α 1D -, but not the α 1A -or α 1B -AR shows basal phosphorylation of ERK1/2 [11] . Incubation with PE of cells stably expressing α 1A -AR rapidly elicits a fast ERK1/2 activation (peak 1-5 min) followed by a slow and progressive reduction of phospho-ERK1/2, which returned to basal levels after 1 h of PE incubation. The α 1B -and α 1D -AR transfected cells underwent a similar initial increase but this was transient and the phospho-ERK1/2 levels were rapidly reduced to basal level. To determine if the α 1 -AR subtype profiles corresponded to the differential regulation of ERK1/2 activation previously described [23, 25] , we studied the early component, potentially G protein-dependent, by blocking PKC with the inhibitor Ro 31-8425 [23] , and employing the receptor-internalization inhibitor ConA [29] , which is known to inhibit endocytosis-dependent ERK1/2 activation [30] . Although DMSO 0.045%, the vehicle of Ro 31-8425, seems to impair the late (N10 min) p-ERK signal after α 1A -AR stimulation ( Fig. 2A, Control) , pre-treatment with Ro 31-8425 resulted in a dramatic decrease (≈70%) in ERK1/2 activation by PE at early time periods (1-5 min) . Fig. 2B shows (Fig. 2C) , the sustained ERK1/2 phosphorylation mediated by activation of the α 1A -AR was significantly affected in cells transfected with β-arrestin2 siRNA.
We performed the same Ro 31-8425, ConA and β-arrestin 2 knockdown treatments on cells expressing α 1B -ARs. As Fig. 3A depicts, pre-treatment with the PKC inhibitor blocked ERK1/2 activation by PE over the entire 60 min period studied. In this case, pre-treatment with ConA or β-arrestin 2 knock-down had no effect on ERK1/2 activation by PE (Fig. 3B, C) . In the HEK293 cells transfected with α 1D -AR, pre-treatment with Ro 31-8425 did not inhibit the early increased phospho-ERK level induced by PE, but extended the period of ERK1/2 phosphorylation because phospho-ERK1/2 levels were higher in the presence of Ro 31-8425 after 10 min of PE incubation (Fig. 4A) . Pretreatment with ConA or β-arrestin 2 siRNA did not modify ERK1/2 phosphorylation kinetics after α 1D -AR activation (Fig. 4B, C) .
The subtype-specific distribution pattern of ERK1/2 activation
An increasing number of studies suggest a differential spatial regulation of ERK1/2 when activated by either G protein-or β-arrestin-dependent pathways [23, 33, 34] . Consensus suggests that ERK1/2 rapidly phosphorylated via G protein-activation, is directed to the nucleus, while ERK1/2 resulting from β-arrestin-mediated activation and scaffolding, exclusively remains in the cytoplasm. Fig. 5A displays confocal images depicting phospho-ERK1/2 localization before (PE 0 min), or 5 and 30 min after PE incubation. Stimulation of α 1A -AR with PE for 5 min, resulted in an increment of phospho-ERK1/2 throughout the cell, including the nucleus as this fraction co-localized with Hoechst nuclear staining. After 30 min, a lower signal was observed, which was restricted entirely to the cytoplasm. Stimulation of α 1B -AR elicited a similar initial (5 min) and transient increase of phospho-ERK1/2 localized in both the cytosol and nucleus. After 30 min of PE stimulation however, no phospho-ERK1/2 signal was observed. Images of the α 1D -AR-transfected cells indicated two main differences from the α 1A and α 1B subtypes: firstly, unstimulated α 1D -AR cells showed higher phospho-ERK1/2 basal levels, thus confirming that α 1D -AR constitutively activates ERK1/2 as found by Western blot; and secondly, activated ERK1/2 was only present in the cytosol and not in the nucleus, even after 5 min of PE incubation when the phospho-ERK1/2 level was maximal. Nuclear localization of phospho-ERK after 5 min of PE incubation was assessed by co-localization analysis of the images, where p-ERK and Hoechst nuclear staining coexisting at the same level is depicted in white (Fig. 5A ).
To determine if the initial phospho-ERK1/2 distribution induced by PE activation (peak 5 min) was PKC-dependent, we performed immunocytochemistry experiments following incubation with the PKC inhibitor Ro 31-8425 before PE stimulation. Although DMSO could slightly modify p-ERK localization to the nucleus after PE 5 min when compared to stimulus without DMSO, Fig. 5B shows confocal images demonstrating that PKC inhibition prevented phospho-ERK1/2 translocation to the nucleus in the α 1A -and α 1B -AR-transfected cells. By contrast, Ro 31-8425 had no effect on either the phospho-ERK1/2 localization after α 1D -AR activation or on the 30-min PE-induced ERK1/2 phosphorylation produced via the α 1A -AR subtype.
Subtype-specific receptor internalization patterns
By N-terminally tagging the three α 1 -AR subtypes with the VSV-G epitope and employing a CypHer-5 dye labeled anti-VSV-G antibody that displays red fluorescence only in an acidic environment [26, 27] , internalization to the acidified endosomes of previously cell surface receptors was monitored in stably transfected, live HEK293 cells. Initially, we localized the three subtypes of α 1 -ARs by confocal microscopy as previously described [11, 12] (Supplemental data 5) and verified that the VSV-G-tagged α 1 -ARs activated ERK1/2 with the same kinetics as the non tagged receptors, this is the VSV-G-α 1A -AR elicits an early and late ERK1/2 activation, while the VSV-G-α 1B -and VSV-G-α 1D -AR only activate ERK1/2 after 5 min but not after 30 min (Supplemental B A Fig. 5 . α 1 -AR stimulation shows a subtype-specific distribution pattern of ERK1/2 activation. 75% confluent HEK293 cells stably expressing each α 1 -AR subtype were serum-starved for 4 h and stimulated with PE (100 μM) for 0, 5 and 30 min at 37°C. These were A) not pretreated with Ro 31-8425 or B) pretreated with Ro 31-8425 15 min before PE addition and vehicle (DMSO). After stimulation, cells were prepared for immunocytochemistry as described under the "Material and methods". Colocalization of p-ERK (green) and Hoechst-stain nuclei (blue) is represented by white in the overlay image. Bar scale represents 10 μm. data 6). Both VSV-G-α 1A -and VSV-G-α 1B -AR, underwent constitutive ( Fig. 6A ) and agonist-induced internalization (Fig. 6B and C) to acidic endosomes. According to our experimental procedure, after 30 min of incubation at 37°C we can observe that the constitutive internalization to endosomes of VSV-α 1B -AR, was inhibited by ConA (Fig. 6A) , an inhibitor of receptor-endocytosis [35] [36] [37] [38] . The phenylephrine induced internalization of VSV-G-α 1A but not that of the VSV-α 1B subtype ( Fig. 6B and C) , was decreased by ConA. We were not able to detect the internalization of the VSV-G-α 1D -AR to acidified endosomes using this approach (results not shown).
Discussion
Some recent studies have shown that after the stimulation of GPCRs, such as the angiotensin AT 1A receptor [23] , β 2 -AR [24] and parathyroid hormone receptors [25] , a pool of ERK1/2 that is activated by the G protein-dependent pathway translocates into the nucleus, whereas activated ERK1/2 that is dependent on β-arrestin-mediated receptor endocytosis, remains in the cytoplasm [23, 33, 34] . In this work, we have characterized a rapid phosphorylation of ERK1/2 that is dependent on α 1A -and α 1B -AR activation of PKC, and promotes p-ERK1/2 translocation to the nucleus. Furthermore, we have also shown that α 1A -, but not α 1B -AR, elicits a sustained activation of ERK1/2 which limits its distribution to the cytoplasm and which is inhibited by β-arrestin 2 knockdown and blocked by the receptor endocytosis-inhibitor ConA, suggesting that the internalized receptor plays a functional role in this signaling process. Distinct expression levels of α 1A -and α 1B -AR could be involved in the differences observed in the time-course of ERK1/2 activation. However, the fact that response was expressed as a percentage of the maximal response in each case minimizes the distortion introduced by the different expression level. In addition, confirming our results, a similar α 1A -dependent activation of ERK1/2 through an endocytic pathway has been recently evidenced in HEK293 cells [39] . Present results show for the first time that the biphasic ERK phosphorylation pattern described for certain GPCRs has been attributed only to the α 1A -subtype and, what is more, that the three different α 1 -AR subtypes present significant differences in this regard (shown schematically in Fig. 7) . Along these lines, we have demonstrated that α 1B -AR elicits a rapid, transient ERK activation, which is PKC-dependent and delivered to the nucleus, but did not show the β-arrestin dependent ERK phosphorylation Fig. 6 . α 1A -and α 1B -AR stimulations show a subtype-specific receptor-internalization pattern and dependency on ConA. 75% confluent HEK293 cells stably transfected with VSV-G-tagged-α 1A -or VSV-G-tagged-α 1B -AR were incubated with the CyPher5 linked anti-VSV antibody at 5 μg/ml for 1 h. After washing with the KRH buffer, cells were mounted in a flow chamber bath and placed in a confocal microscope stage in a 95% air and 5% CO 2 atmosphere at 37°C. At this time, cells were pre-warmed with the KRH buffer supplemented or not supplemented with ConA (250 μg/ml) for 30 min and the constitutive internalization was measured (A). At this point, phenylephrine (PE) 100 μM was added and agonist-induced internalization of α 1A and α 1B -ARs was quantified for 30 min (B and C respectively) as described in "Material and methods". Statistics was performed by two way ANOVA (P b 0.05) and by Student's t-test to compare internalization at each time. ***P b 0.001, **P b 0.01, and *P b 0.05 vs. control or PE. Bar scale represents 20 μm.
observed with the α 1A -subtype. Although α 1D -AR also shows an early, transient ERK activation after agonist stimulation, this initial peak is not only independent of PKC and β-arrestin, but is also confined to the cytosol, which therefore increases the complexity of the α 1 -AR signaling network. Exactly why α 1D -AR activates ERK through a distinct pathway is an open question that needs to be investigated further.
At this point, it is interesting to note that both the α 1A and α 1B receptors internalize upon agonist activation but ConA, a well-known receptor-internalization blocker [35] [36] [37] [38] , only abolishes agonistmediated internalization of α 1A -AR. When we analyzed the internalization together to ERK phosphorylation kinetics elicited by either α 1A -or α 1B -AR, we found that maximal α 1A -AR internalization was achieved 5 min after PE stimulation but a sustained ERK activation located in the cytosol and inhibited by β-arrestin 2 knockdown and ConA was observed even when the receptor was maximally internalized. Conversely, agonist induced internalization of the α 1B -AR, by a mechanism that, in our experimental conditions, is unaffected by β-arrestin 2 knockdown or treatment with ConA, was almost maximal at 10 min but, at this time, ERK1/2 phosphorylation had already returned to basal levels, suggesting that the internalized receptor was not able to activate ERK1/2. All these findings suggest that α 1A -AR, when stimulated by PE, internalizes via a ConA-sensitive mechanism responsible for the late PKC-independent ERK activation and this relates to the antiapoptotic activity of the α 1A subtype. Thus, differences in the internalization mechanisms lead to different intracellular signaling pathways for each subtype, which could explain why anti-apoptotic activity, could be exhibited only by the α 1A subtype. In this regard, it has been previously found that the α 1B -subtype shows a stronger interaction with β-arrestin than the α 1A -AR [19] . Our results are compatible with these previous observations. In our hands, the constitutive internalization of the α 1B -subtype was inhibited by ConA, but the subsequent addition of the agonist gives a similar profile of internalization independent of the presence of ConA, suggesting that receptorinternalization of the α 1B -AR was, at this time, completed. Therefore, it would be interesting to further study the different mechanisms of internalization in order to establish why the α 1A -AR, which shows a weaker interaction with β-arrestin, elicits a late ERK1/2 activation dependent on endosomic internalization, while the α 1B -AR does not.
Little is known about the role of a differential ERK distribution in the cell. Nuclear p-ERK substrates, particularly transcription factors, have been extensively studied but cytoplasmic substrates have been the object of less scrutiny. However, several examples suggest that cytoplasmic ERK activity is important in cell viability and apoptosis [40, 41] and it has been established that the cyto-protective activity of other GPCR as AT 1A receptors is related to β-arrestin 2 dependent activation of cytosolic ERK. In the same way, perinuclearly localized α 1A -ARs, but not α 1B or α 1D -AR, has been shown that exerts an antiapoptotic and cardioprotective role in cardiomyocytes, which is mediated by ERK activation [42] .
On the other hand, it has been recently shown that the wild-type and a genetic variant of the α 1A -AR transactivate EGFR via a β-arrestin-dependent mechanism [43] . The parallelism between this mechanism and the β 1 -AR mediated EGFR transactivation, which confers cardioprotection [44, 45] suggests that EGFR transactivation could be involved in the antiapoptotic and cardioprotective activity of the α 1A -subtype.
Therefore, previous evidences and present results strongly suggest that the cytosolic-confined pool of p-ERK activated by α 1A -AR in a G protein-independent β-arrestin dependent fashion, probably via EGFR transactivation [43] , is a prosurvival pathway relevant for cardioprotection, and could explain the clinical evidence that chronic use of non subtype selective α 1 antagonists as doxazosin was associated with higher risk factor for coronary heart disease [46, 47] . Future work in the field could be necessary to establish the exact role of EGFR transactivation on the G protein-independent, β-arrestin dependent retention of p-ERK in the cytoplasm elicited by α 1A -AR activation.
Previous studies have identified constitutive activity of α 1D -AR; that is, activity in the absence of agonist stimulus [11, [13] [14] [15] [16] . In order to analyze potential constitutive activation of ERK1/2, we compared basal phosphorylation state in the cells transfected with each α 1 -AR subtype. As Supplemental Fig. 3 shows, α 1D -AR-transfected cells showed the highest phospho-ERK1/2 basal level and treatment with α 1 -antagonists such as prazosin (PZ, a non selective α 1 antagonist) and BMY 7378 (a selective α 1D antagonist), decreased this basal ERK1/2 phosphorylation, thus confirming that α 1D -AR constitutively activates ERK1/2 and that these compounds act as inverse agonists, as previously concluded [11, [13] [14] [15] [16] . Unfortunately, we were not able to observe internalization of α 1D -AR using CypHer5 technology and the VSV-G-tagged receptor. As previously described, α 1D -AR is intracellularly distributed [12] and has shown striking difficulties when attempts to detect it have been made [48] . We hypothesize two reasons why we were not able to detect VSV-G-tagged α 1D -AR: first, a CypHer-5-antiVSV-G-tagged receptor is visible only in the acidic pH environment of an internalized endosome [26] , meaning that active internalization is needed to visualize the receptor. If α 1D -AR is predominantly intracellular it would not be labeled by the antibody and detected by the CypHer5 dye. In fact, previous works strongly suggest that the α 1D -AR is constitutively active and, as a result, is localized to intracellular compartments involving β-arrestin2 internalization [11] . Second, it is possible that the trafficking pattern of VSV-G-α 1D -AR could be modified by VSV-G-tagging, because the characteristic distribution of α 1D -AR appears to be related to its long N-terminal domain [49] , where the VSV-G-tag is placed.
Additional experiments are required to clarify this point, as well as the physiological meaning of both the constitutive and PE-induced ERK1/2 phosphorylation mediated by the α 1D -AR that is not dependent on PKC activation and is restricted to the cytosol.
Conclusions
The present study reveals that the three α 1 -AR subtypes present different spatio-temporal patterns of ERK phosphorylation and receptor internalization. Only α 1A -AR elicits a late and sustained ERK phosphorylation that is dependent on receptor-internalization and is restricted to the cytosol. This late ERK activation may relate to the antiapoptotic-cardioprotective effect of α 1A -AR. 
